CagriSema
Cagrilintide + Semaglutide
CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.
Mecanismo de Ação
Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.
Protocolos de Pesquisa
Para fins de pesquisa apenas. Não é conselhos médicos.
Research protocols use the combination in a single weekly injection. Phase 3 doses range from cagrilintide 2.4mg + semaglutide 2.4mg weekly.
Notas de Pesquisa
Clinical Research Status
CagriSema is in Phase 3 trials (REDEFINE program) for obesity and type 2 diabetes, with regulatory submissions anticipated based on trial readouts. Phase 2 data demonstrated approximately 15.6% body weight loss at 32 weeks, numerically superior to semaglutide 2.4mg alone. The REDEFINE 1 Phase 3 trial reported up to 22.7% weight loss at 68 weeks, positioning it competitively against tirzepatide.
Key Published Findings
The dual amylin/GLP-1 approach produces additive weight loss beyond either mechanism alone, supporting the hypothesis that multi-receptor targeting enhances metabolic outcomes. Glycemic improvements were also observed, with potential for combined diabetes and obesity indications. The mechanistic rationale rests on amylin's distinct CNS satiety signaling through the area postrema complementing GLP-1's hypothalamic and gut-mediated effects.
Safety Profile
The adverse event profile combines elements of both components, with gastrointestinal effects (nausea, vomiting, diarrhea) being most common during dose escalation. Tolerability appears manageable with appropriate titration schedules, though direct comparisons to monotherapy discontinuation rates are still being evaluated. Injection site reactions are consistent with other subcutaneous peptide therapies.
Comparison to Related Compounds
CagriSema competes directly with tirzepatide (Mounjaro/Zepbound), which uses a single molecule targeting GIP and GLP-1 receptors simultaneously. The two-molecule approach allows independent dose optimization of each component but requires a single co-formulated injection. Weight loss magnitude appears comparable to tirzepatide's 20-25% in similar trial durations, though head-to-head data is needed for definitive comparison.
Community Observations
The obesity research community views CagriSema as Novo Nordisk's answer to tirzepatide's superior weight loss over semaglutide monotherapy. Clinicians note that the combination format may offer flexibility for patients who plateau on GLP-1 monotherapy. The amylin component is reported to address residual hunger that some patients experience even at maximum GLP-1 doses.
Meio-Vivo
~7 days (combination)
Reconstituição
Pre-mixed formulation
Armazenamento
Liofilizado
Refrigerate 2-8C.
Reconstituído
Refrigerate 2-8C. Use within 42 days.
Situação Legal nos EUA
Também Conhecido Como
Perguntas frequentes
O que é CagriSema?
CagriSema is a fixed-ratio combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (a long-acting amylin analog), both developed by Novo Nordisk. This dual-mechanism injectable targets two complementary appetite and metabolic pathways simultaneously. It is in Phase 3 clinical trials and represents Novo Nordisk's next-generation obesity treatment strategy following semaglutide monotherapy.
Como CagriSema funciona?
Fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Targets three distinct appetite and metabolic pathways simultaneously.
Qual é o status regulatório de CagriSema nos EUA?
Research chemical (not FDA-approved)
Qual é a meia-vida de CagriSema?
~7 days (combination)
Por quais outros nomes CagriSema é conhecido?
Cagrilintide + Semaglutide
Peptide Contacts fornece resumos baseados em pesquisas apenas para fins informativos. Não hospedamos, distribuímos ou endossamos documentação de fornecedores. Todas as certificações de análise completa, certificados GMP e comunicações de fornecedores devem ser solicitadas e verificadas diretamente pelo comprador. Nada nesta plataforma constitui conselhos legais, médicos ou profissionais. Os usuários são unicamente responsáveis por verificar as credenciais dos fornecedores e garantir a conformidade com todas as leis locais, estaduais e federais aplicáveis antes de adquirir qualquer química de pesquisa. O uso desta plataforma constitui aceitação plena da responsabilidade pessoal.
Leia a declaração completa